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IgA nephropathy (IgAN) is the most common form of glomerulonephritis and a 
principal cause of end-stage renal disease (ESRD) throughout the world.1 Selectins are 
cell-to-cell adhesion molecules involved in the leukocyte-endothelial cell interaction 
leading to leukocytic infiltration into tissue.2 Leukocytic infiltration into the glomerulus 
and renal interstitium appears to be critical for the pathogenesis of IgAN.  
 Granulocyte-colony stimulating factor (G-CSF) is widely used to induce 
neutrophil production after myelosuppressive treatment and to mobilize bone marrow 
hematopoietic progenitors which are provided for hematopoietic stem cell 
transplantation (HSCT) recipients. Although G-CSF is normally safely administered, it 
has been associated with rare but serious toxicities including splenic rupture, allergic 
reactions, flares of underlying autoimmune disorders and vascular complications,3,4 as 
previously reviewed by Tigue et al. in this journal5, as well as hematological 
malignancies6. 
 G-CSF induces E-selectin expression on endothelial cells7 and E-selectin 
ligand (CD44) expression on mobilized, circulating leukocytes.8 Therefore, enhanced 
leukocyte-endothelial cell interactions due to the upregulation of both E-selectin and 
CD44 may play a crucial role in the pathobiology of G-CSF-associated vascular 
complications. This report describes a previously healthy 7-year-old male who 
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developed IgAN after the administration of G-CSF.  
 
 A 7-year-old boy was hospitalized to serve as a donor for his sister with 
juvenile myelomonocytic leukemia and who was scheduled to undergo peripheral blood 
SCT. He had no significant past medical history. He had undergone regular health 
checkups at school, including the latest urinalysis 3 months before hospitalization, and 
all findings had been normal. There was no renal disorder among either his family or 
relatives. He was given 300 µg (12.5 µg/kg) of filgrastim (GRAN®; Kyowa Hakko 
Kirin Co., Ltd., Tokyo, Japan) on days 1 to 3 once daily, and 375 µg (15.6 µg/kg) twice 
on day 4 subcutaneously. On day 5, he was given the final dose (375 µg) of filgrastim 
and thereafter underwent leukapheresis without any adverse reactions. He was 
discharged shortly after completion of the procedure.  
 Thirteen days after the first dose of filgrastim, he presented with general 
fatigue. A physical examination showed no abnormality. His blood pressure was normal 
and he had no fever. The hematological examination was normal. The blood urea 
nitrogen was 13.8 mg/dl, serum creatinine was 40.7 µmol/L, and creatinine clearance 
was 51 ml/min. Serological tests for antinuclear antibody were negative. The levels of 
serum complement factors C3 and C4 were normal. The concentrations (normal ranges) 
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of the serum IgG, IgA and IgM were 776 (670-1,560), 134 (48-276), and 146 (85-337) 
mg/dl, respectively. The urinalysis revealed hematuria (1+) and proteinuria (3+). He 
underwent a kidney biopsy 33 days after the first dose of filgrastim, because of the 
persistent hematuria and proteinuria. Histological studies of the biopsied specimen 
revealed prominent IgA deposition on the mesangium with mesangial and endocapillary 
proliferation, which was compatible with the acute phase of IgAN. He was treated with 
a cocktail therapy consisting of prednisolone, azathioprine, warfarin, and dipyridamole 
on day 75 after the first dose of filgrastim because his urinary findings remained 
abnormal, He responded to the treatment quickly, and his urinalysis was normalized by 
day 99. His urinalysis remained normal until the latest visit on day 462 after the first 
dose of filgrastim. 
 Indirect immunofluorescence staining was performed using monoclonal 
antibodies P2H3 and DF1485 against E-selectin and CD44, respectively (Santa Cruz 
Biotechnolgy, Inc., Santa Cruz, California, U.S.A). The expression of E-selectin in the 
glomerulus was evident in this patient (Figure 1A), but not in any other patients with 
IgAN untreated with filgrastim (Figure 1B) or a normal control (data not shown). 
Furthermore, CD44 expression was also demonstrated in the glomerulus of the patient, 
but not in the normal control (data not shown). 
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 G-CSF has a number of biological functions, thus providing several clinical 
applications. Notably, it is administered to many healthy individuals who have served as 
donors for HSCT; therefore, the safety issues regarding its administration are crucial. It 
is very important to report severe toxicities developing in G-CSF derived PBSC donors, 
especially in the case of children6. The reported adverse effects include bone pain, 
headache or general fatigue following G-CSF administration in approximately 30% of 
all cases.9 Furthermore, although rare, vasculitic complications, such as coronary artery 
disease and capillary leak syndrome, and hematological malignancies can also 
sometimes result in a serious outcome.3-6 
 IgAN, initially considered to be benign, leads to ESRD within 20 years in 
approximately 40% of patients.1 This report suggests that G-CSF administration might 
be linked to IgAN in a previously healthy donor, based on the chronological sequence 
and the recent findings that G-CSF induces the expression of E-selectin7 and its ligand8 
which are the key factors involved in the pathogenesis of IgAN. It should be also noted 
that the donor was given a relatively high dose of G-CSF (31.2 µg/kg/day on day 4), 
because of the critical clinical condition of the recipient. This suggests that the donor in 
the current case may have been genetically susceptible to IgAN and thus the 
administration of high dose of G-CSF may have induced the donor to subsequently 
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develop IgAN. Although IgAN has never previously been considered to be an adverse 
effect of G-CSF, and it is not possible to prove this hypothesis experimentally, it is 
nevertheless important to note that G-CSF administration may cause IgAN, a principal 
cause of ESRD worldwide, in susceptible individuals.  
 It is important to note that selectin gene polymorphisms have been suspected to 
play a role in the development and/or progression of IgAN9. The establishment of a 
method(s) to carefully screen and identify individuals genetically susceptible to IgAN 
and other vascular events may help avoid this rare but serious complication of G-CSF in 
such donors. Furthermore, genetic susceptibility may account for the increased risk of 
myelodysplastic syndrome among breast cancer patients receiving G-CSF10 or other 
G-CSF-related toxicities. Accumulation and analyses of cases are required. 
 Finally, while G-CSF should not be assumed to be risk-free, its benefits still 
overweigh the risk. Extensive investigation on its safety and toxicity in pediatric 
population is essential. 
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Figure 1. E-selectin expression in the patient’s renal section specimens.  
(A) E-selectin expression is widely distributed in the glomerulus of the patient. 
(B) E-selectin expression is not obvious in another IgAN patient. 
